Transaction in Own Shares

Summary by AI BETAClose X

The Biotech Growth Trust PLC announced on October 24, 2025, the market purchase of 88,524 of its own ordinary shares at a price of 1087.85 pence per share for cancellation. This purchase was made under the authority granted at the Annual General Meeting held on July 17, 2025, with a maximum allowance of 3,802,717 shares. Following this transaction, the total number of ordinary shares in issue, less those bought back for cancellation, resulting in a total number of voting rights in the Company of 22,406,234. The company does not currently hold any ordinary shares in treasury.

Disclaimer*

For immediate re lease

24 October 2025

 

THE BIOTECH GROWTH TRUST PLC

(the "Company")

 

 

MARKET PURCHASE OF COMPANY'S OWN SHARES

 

 

 

Notification is given, pursuant to the authority granted at the Annual General Meeting of the Company held on 17 July 2025 to make market purchases of the Company's own shares up to an aggregate maximum of 3,802,717 that a market total of 88,524 Ordinary shares of 25p each in the capital of the Company were purchased today for cancellation by the Company at a price of 1087.85 pence per share.

 

Following this transaction, the Company hereby notifies the market that the total number of Ordinary shares that the Company has in issue, less the total number of Ordinary shares bought back for cancellation by the Company following such purchase, and therefore, the total number of voting rights in the Company 22,406,234. The Company does not currently hold any Ordinary shares in treasury.

 

The figure of 22,406,234 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For and on behalf of

Frostrow Capital LLP

Company Secretary

 

For further information, please contact:

 

Katherine Manson

Frostrow Capital LLP

Tel: 020 3709 8734




UK 100

Latest directors dealings